SG Americas Securities LLC Has $627,000 Position in GSK PLC Sponsored ADR $GSK

SG Americas Securities LLC cut its holdings in GSK PLC Sponsored ADR (NYSE:GSK) by 51.2% during the first quarter, according to its most recent Form 13F filing with the SEC. The firm owned 11,363 shares of the pharmaceutical company’s stock after selling 11,905 shares during the period. SG Americas Securities LLC’s holdings in GSK were worth $627,000 as of its most recent filing with the SEC.

Several other large investors have also made changes to their positions in the business. IHT Wealth Management LLC grew its holdings in GSK by 1.3% in the 4th quarter. IHT Wealth Management LLC now owns 15,010 shares of the pharmaceutical company’s stock valued at $736,000 after buying an additional 188 shares during the last quarter. Coston McIsaac & Partners lifted its holdings in shares of GSK by 17.3% during the fourth quarter. Coston McIsaac & Partners now owns 1,395 shares of the pharmaceutical company’s stock worth $68,000 after buying an additional 206 shares during the last quarter. First Horizon Corp lifted its holdings in shares of GSK by 78.7% during the fourth quarter. First Horizon Corp now owns 536 shares of the pharmaceutical company’s stock worth $26,000 after buying an additional 236 shares during the last quarter. Peoples Bank KS boosted its position in shares of GSK by 6.3% in the fourth quarter. Peoples Bank KS now owns 5,030 shares of the pharmaceutical company’s stock valued at $247,000 after acquiring an additional 300 shares during the period. Finally, Syon Capital LLC grew its stake in shares of GSK by 1.3% in the fourth quarter. Syon Capital LLC now owns 29,073 shares of the pharmaceutical company’s stock worth $1,426,000 after acquiring an additional 382 shares during the last quarter. Institutional investors and hedge funds own 15.74% of the company’s stock.

GSK Stock Up 0.3%

Shares of GSK stock opened at $53.23 on Wednesday. GSK PLC Sponsored ADR has a one year low of $35.45 and a one year high of $61.69. The company has a debt-to-equity ratio of 0.80, a current ratio of 0.79 and a quick ratio of 0.52. The stock has a fifty day moving average price of $51.49 and a 200 day moving average price of $53.18. The stock has a market cap of $107.81 billion, a P/E ratio of 13.83, a price-to-earnings-growth ratio of 3.41 and a beta of 0.35.

GSK Cuts Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, July 9th. Stockholders of record on Friday, May 15th will be issued a dividend of $0.44 per share. This represents a $1.76 dividend on an annualized basis and a dividend yield of 3.3%. The ex-dividend date of this dividend is Friday, May 15th. GSK’s dividend payout ratio (DPR) is presently 47.01%.

Analyst Upgrades and Downgrades

A number of equities analysts recently issued reports on GSK shares. HSBC raised shares of GSK from a “reduce” rating to a “hold” rating in a research report on Monday. Royal Bank Of Canada restated an “outperform” rating on shares of GSK in a research report on Tuesday, June 9th. Wall Street Zen upgraded shares of GSK from a “hold” rating to a “buy” rating in a report on Saturday, June 27th. Finally, Weiss Ratings lowered shares of GSK from a “buy (b)” rating to a “buy (b-)” rating in a research report on Thursday, June 11th. Three investment analysts have rated the stock with a Buy rating, five have issued a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat.com, GSK currently has an average rating of “Hold” and an average price target of $53.00.

GSK Company Profile

GSK (GlaxoSmithKline plc) is a London-headquartered, multinational pharmaceutical and healthcare company formed through the 2000 merger of Glaxo Wellcome and SmithKline Beecham. The company is dual-listed and operates globally, developing, manufacturing and commercializing prescription medicines, vaccines and specialty treatments. Over its history GSK has evolved through portfolio reshaping and strategic transactions to focus on science-led pharmaceuticals and vaccines.

GSK’s core activities include research and development of therapies and vaccines across a range of therapeutic areas, commercial manufacturing, and global marketing.